Dianthus Therapeutics, Inc. (DNTH) Stock Price & How to Invest
Last updated July 2026
Short answer
Dianthus Therapeutics (DNTH) is a clinical-stage biotech whose entire investment case rides on claseprubart (DNTH103), a selective classical-complement (C1s) inhibitor now in Phase 3 for CIDP and generalized myasthenia gravis, so it trades as a binary bet on trial data rather than on current earnings.
DNTH stock price
As of 2026-07-17, Dianthus Therapeutics, Inc. (DNTH) last closed at $105.60, up 417.6% over the past year. Over the past 52 weeks it has traded between $18.76 and $105.60.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Dianthus Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Dianthus Therapeutics, Inc. (DNTH) do?
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing claseprubart (DNTH103), an antibody that selectively blocks the active form of the C1s enzyme in the complement system's classical pathway while leaving the alternative and lectin pathways intact to preserve immune defense. Using half-life-extension (YTE) technology, the drug is designed for infrequent, low-volume subcutaneous self-injection (as seldom as once every four weeks), which the company positions as a convenience advantage over infused or more frequently dosed rivals. The lead programs target rare autoimmune and neuromuscular diseases: chronic inflammatory demyelinating polyneuropathy (CIDP), generalized myasthenia gravis (gMG), and multifocal motor neuropathy (MMN).
As a pre-revenue company, DNTH's value is driven by pipeline progress rather than sales. In 2026 it reported an early GO decision in the Phase 3 CAPTIVATE CIDP trial after an interim responder analysis, positive Phase 2 MaGic data in gMG, and initiation of the Phase 3 EMERGE trial in gMG, with a Phase 2 MMN readout expected in the second half of the year. A large upsized equity raise pushed cash to roughly $1.2 billion and extended runway into 2030, giving the company the balance sheet to fund multiple late-stage trials, though it also means the stock carries the concentrated, all-or-nothing risk profile typical of single-asset biotech.
What's driving Dianthus Therapeutics, Inc. (DNTH)?
1. Phase 3 CIDP readout (CAPTIVATE)
The classical pathway is heavily implicated in CIDP, and Dianthus announced an early GO decision after an interim responder analysis, which the market read as a positive de-risking signal. Topline guidance for Part B of CAPTIVATE is expected by the end of 2026, making it the single most important catalyst for the stock.
2. Generalized myasthenia gravis expansion
Positive Phase 2 MaGic data supported a best-in-class narrative, and the Phase 3 EMERGE trial in gMG began in mid-2026. gMG is a competitive but growing market where success would give claseprubart a second large indication beyond CIDP.
3. Dosing and convenience differentiation
Selective C1s inhibition aims to spare the rest of the immune system, and YTE half-life extension enables a roughly 10-second self-injection dosed as infrequently as every four weeks. If efficacy holds, that profile could be a commercial differentiator against infused C5 inhibitors and more frequently dosed FcRn agents.
4. Pipeline breadth across rare neuromuscular disease
Beyond CIDP and gMG, an ongoing Phase 2 MMN trial with a second-half-2026 readout adds optionality, letting one molecule address several complement-driven autoimmune indications and spreading clinical risk across programs.
What are the risks to Dianthus Therapeutics, Inc. (DNTH)?
As a pre-revenue, essentially single-asset company, DNTH faces concentrated clinical risk: a failed or ambiguous Phase 3 readout in CIDP or gMG could sharply reduce the value of the entire pipeline. The complement and neuromuscular space is crowded with well-capitalized competitors including argenx, UCB, and AstraZeneca's Alexion, so even successful approval would face commercial and pricing pressure. The company is not yet profitable and continues to burn cash on multiple late-stage trials, and while runway extends into 2030, further dilution is possible if timelines slip. Regulatory outcomes, safety findings, and the durability of the convenience advantage all remain unproven at scale.
How is Dianthus Therapeutics, Inc. (DNTH) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Dianthus Therapeutics, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$0 (pre-revenue clinical stage)
- Market cap: ~$4.7-4.9B
- Cash & equivalents: ~$1.2B (as of Q1 2026)
- Cash runway: into 2030
- Net income (TTM): negative (R&D-driven losses)
- Lead asset stage: claseprubart in Phase 3 (CIDP, gMG)
Standard valuation multiples do not apply because Dianthus has no product revenue and runs at a loss funding clinical trials. The roughly $4.8 billion market cap reflects investor expectations for claseprubart across CIDP, gMG, and MMN, so the stock is priced on probability-weighted future approvals rather than current fundamentals. The ~$1.2 billion cash balance and runway into 2030 give it unusual financial strength for a clinical-stage name.
Who competes with Dianthus Therapeutics, Inc. (DNTH)?
FcRn inhibitors
argenx (Vyvgart/efgartigimod) and Johnson & Johnson's nipocalimab compete in gMG and expanding autoimmune indications by lowering pathogenic IgG antibodies, a different mechanism that targets similar patient populations.
Complement (C5) inhibitors
AstraZeneca's Alexion (Soliris/Ultomiris/eculizumab-ravulizumab) and UCB's zilucoplan block the terminal complement pathway in gMG and related diseases; Dianthus differentiates by inhibiting the upstream, active C1s to spare the alternative and lectin pathways.
Broader rare-autoimmune and neuromuscular biotech
Other clinical-stage and commercial players pursuing CIDP, MMN, and complement-mediated disorders compete for the same rare-disease patients, physicians, and payer budgets, making commercial differentiation on efficacy and dosing critical.
How to invest in Dianthus Therapeutics, Inc. (DNTH)
There are three common ways to get DNTH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so DNTH sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where DNTH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Dianthus Therapeutics, Inc. (DNTH)
DNTH is a well-funded, single-asset neuroimmunology story where the ~$4.8B valuation reflects Phase 3 expectations, not revenue, making trial readouts the thing that matters most.
More on Dianthus Therapeutics, Inc. (DNTH)
Whether DNTH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DNTH a buy?, and where the stock could go from here in the DNTH stock forecast.
For income investors, whether DNTH pays a dividend and how the payout looks is covered in does DNTH pay a dividend?
Build a basket around DNTH with Walnut
Use Dianthus Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Dianthus Therapeutics do?
+
It is a clinical-stage biotech developing claseprubart (DNTH103), an antibody that selectively blocks the active C1s enzyme in the complement system's classical pathway, for rare autoimmune and neuromuscular diseases such as CIDP, generalized myasthenia gravis, and MMN.
Is DNTH profitable?
+
No. As of July 2026 Dianthus is pre-revenue and runs at a loss, spending on research and clinical trials. Its value is based on pipeline potential rather than earnings, which is typical for a clinical-stage biotech.
What is claseprubart (DNTH103)?
+
It is Dianthus's lead drug candidate, a monoclonal antibody targeting the active form of C1s to inhibit the classical complement pathway while preserving other immune pathways. YTE half-life extension allows infrequent, low-volume subcutaneous self-injection.
What are DNTH's key catalysts in 2026?
+
The main catalysts include topline guidance for Part B of the Phase 3 CAPTIVATE CIDP trial expected by year-end 2026, the newly initiated Phase 3 EMERGE trial in gMG, and a Phase 2 MMN readout expected in the second half of 2026.
How much cash does Dianthus have?
+
The company reported roughly $1.2 billion in cash as of Q1 2026, bolstered by a large upsized equity offering, with a runway projected into 2030. That gives it a strong balance sheet to fund multiple late-stage trials.
Who are DNTH's main competitors?
+
Competitors include FcRn inhibitors like argenx's Vyvgart and J&J's nipocalimab, terminal complement (C5) inhibitors from AstraZeneca's Alexion and UCB, and other rare-autoimmune biotechs targeting CIDP, gMG, and MMN patients.
Why is DNTH considered high risk?
+
Because it is essentially a single-asset, pre-revenue company, a disappointing Phase 3 readout could sharply cut the value of the whole pipeline. Clinical, regulatory, competitive, and dilution risks all remain, so the stock behaves as a binary bet on trial data.
What differentiates claseprubart from other treatments?
+
It selectively targets the active C1s enzyme to block only the classical complement pathway, aiming to preserve broader immune defense, and its half-life-extension technology enables a roughly 10-second self-injection dosed as infrequently as every four weeks versus longer infusions for some rivals.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Dianthus Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.